These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 6378118)
21. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193 [TBL] [Abstract][Full Text] [Related]
22. Levomepromazine elimination in patients during active and sham hemodialysis. Andersson SB; Forshell GP; Schulman A; Wetterberg L; Asaba H Artif Organs; 1983 Aug; 7(3):340-3. PubMed ID: 6625964 [TBL] [Abstract][Full Text] [Related]
23. A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. Goff DC; Amico E; Dreyfuss D; Ciraulo D Am J Psychiatry; 1994 Mar; 151(3):429-31. PubMed ID: 8109654 [TBL] [Abstract][Full Text] [Related]
24. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets. Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786 [TBL] [Abstract][Full Text] [Related]
25. Is positive placebo response in chronic schizophrenia investigator-dependent? Taiminen T; Syvälahti E; Saarijärvi S; Niemi H; Lehto H; Ahola V; Salokangas RK J Nerv Ment Dis; 1997 Oct; 185(10):644-5. PubMed ID: 9345257 [No Abstract] [Full Text] [Related]
26. Dialysis in schizophrenia: a double-blind evaluation. Schulz SC; van Kammen DP; Balow JE; Flye MW; Bunney WE Science; 1981 Mar; 211(4486):1066-8. PubMed ID: 7466380 [TBL] [Abstract][Full Text] [Related]
27. Dialysis for schizophrenia: review of clinical trials and implications for further research. Fogelson DL; Marder SR; Van Putten T Am J Psychiatry; 1980 May; 137(5):605-7. PubMed ID: 7369409 [TBL] [Abstract][Full Text] [Related]
28. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Kramer MS; Last B; Getson A; Reines SA Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198 [TBL] [Abstract][Full Text] [Related]
29. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. Kramer MS; Vogel WH; DiJohnson C; Dewey DA; Sheves P; Cavicchia S; Little P; Schmidt R; Kimes I Arch Gen Psychiatry; 1989 Oct; 46(10):922-8. PubMed ID: 2679483 [TBL] [Abstract][Full Text] [Related]
30. Hemodialysis in schizophrenia: psychiatric aspects of treatment failure in a pilot study. Rorsman B; Franzén G; Sjöstedt L; Lindholm T; Thysell H; Terenius L; Wahlström A Neuropsychobiology; 1981; 7(3):127-36. PubMed ID: 6112716 [TBL] [Abstract][Full Text] [Related]
31. Risperidone in treatment-refractory schizophrenia. Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947 [TBL] [Abstract][Full Text] [Related]
32. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Woods SW; Gueorguieva RV; Baker CB; Makuch RW Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728 [TBL] [Abstract][Full Text] [Related]
33. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned. Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151 [TBL] [Abstract][Full Text] [Related]
34. The effects of ceruletide in schizophrenia. Hommer DW; Pickar D; Roy A; Ninan P; Boronow J; Paul SM Arch Gen Psychiatry; 1984 Jun; 41(6):617-9. PubMed ID: 6329121 [TBL] [Abstract][Full Text] [Related]
35. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196 [TBL] [Abstract][Full Text] [Related]
36. A high-dose, double-blind study of ceruletide in the treatment of schizophrenia. Mattes JA; Hom W; Rochford JM Am J Psychiatry; 1985 Dec; 142(12):1482-4. PubMed ID: 3907376 [TBL] [Abstract][Full Text] [Related]
37. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345 [TBL] [Abstract][Full Text] [Related]
39. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Danion JM; Rein W; Fleurot O Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]